Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Jad M Abdelsattar, M.D, FACS

Breast Surgical Onc · University of Oxford

View

Dr. Lauren Kopicky

Breast Surgical Onc · Cleveland Clinic

View

Dr. Jennifer Plichta

Breast Surgical Onc · Duke University

View

Dr. Sarah Blair

Breast Surgical Onc · UCSD

View

Dr. Karen Goodwin

Breast Surgical Onc · UCSF

View

Dr. Christin Collins

Breast Surgical Onc · MetroHealth

View

Dr. Philip Schauer

Bariatric Surgery · PBRC

View

Dr. Todd Rosengart

Cardiac Surgery · BCM

View

Dr. Larry Kaiser

Thoracic Surgery · UPenn

View

Dr. Neri Cohen

Thoracic Surgery · XVIVO

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    LEDr. Laura Esserman

    Dr. Laura Esserman

    Surgery · Breast Surgical Oncology
    University of California San Francisco Medical Center
    laurae
    Jul 24, 2025Clinical Trial, Phase II

    Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial.

    ​
    ​
    ​+3

    Written by 5 Roon authors & 31 others

    Via Annals of Surgical Oncology

    Research

    Detection of serum HER2 in patients treated with neratinib or trastuzumab: analysis of the I-SPY Trial.

    2025

    Via Frontiers in Oncology

    Aug 23, 2025Journal Article

    Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial.

    ​
    ​
    ​+2

    Written by 4 Roon authors & 29 others

    Via Annals of Surgical Oncology

    Research

    Integrating breast cancer polygenic risk scores at scale in the WISDOM Study: a national randomized personalized screening trial.

    2025

    Via Genome Medicine

    Research

    Immune and Growth Factor Signaling Pathways Are Associated with Pathologic Complete Response to an Anti-Type I Insulin-like Growth Factor Receptor Regimen in Patients with Breast Cancer.

    2025

    Via Clinical Cancer Research

    Research

    Organoid-evaluable clinical biomarkers predict drug responses and guide new breast cancer therapies.

    2025

    Via bioRxiv

    Research

    Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast Cancer.

    2025

    Via medRxiv

    Research

    FNA biopsy of breast specimens effectively harvests cells for patient-derived organoids modeling ductal carcinoma in situ.

    2025

    Via Cancer Cytopathology

    Research

    CHFR expression and sensitivity of breast cancer cells to antimitotic agents in vitro and in the I-SPY trial.

    2025

    Via NPJ Breast Cancer

    Research

    Progesterone receptor (PR) intra-tumor heterogeneity in premenopausal breast cancer: A secondary analysis of a randomized trial.

    2025

    Via International Journal of Cancer

    Research

    Systematic data capture reduces the need for source data verification: exploratory analysis from a phase 2 multicenter randomized controlled platform trial.

    2025

    Via Communications Medicine

    Research

    WISDOM Randomized Trial Comparing Risk-Based Versus Annual Breast Cancer Screening: Study Cohort Characteristics and Design.

    2025

    Via Research Square

    Research

    Multicenter Interspecialty Consensus on Experimental Oncology Drug-Related Ocular Adverse Event Reporting.

    2025

    Via JAMA Ophthalmology

    Research

    Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors.

    2025

    Via Nature Communications

    Research

    Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial.

    2025

    Via JAMA